PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 2, 2026Nature Communications2 citationsOpen Access

High-throughput methods leveraging robotics and computer vision for the development of therapeutic phage cocktails

View Full Paper
TPTaylor J. R. PenkeProfectus Biosciences (United States)AHA. T. HammackLawrence Berkeley National LaboratoryLMLana J. McMillanProfectus Biosciences (United States)

Key Points

  • The aim is to develop efficient methods for creating therapeutic phage cocktails to treat bacterial infections.
  • Utilized high-throughput automated screening techniques.
  • Integrated liquid handling robotics with phenotypic assays.
  • Employed computer vision for phage enumeration.
  • Screened phage collections against bacterial strains in clinical trials.
  • Established a reproducible screening platform for phage-bacteria interactions.
  • Successfully identified and optimized effective phage cocktails with broad activity.
  • Addressed the gap in scalable phage combination development for antibiotic resistance.

Abstract

Abstract We present the high-throughput automated screening techniques that are being used to develop bacteriophage-based therapeutic products currently under investigation in human clinical trials to combat urinary tract infections 1 . By integrating modern liquid handling robotics, standardized phenotypic assays, and computer vision-based enumeration, we established a platform capable of reproducibly screening large collections of phages against clinically derived bacterial strain panels. This approach enabled systematic assessment of phage-bacteria interactions at scale, facilitating the identification and optimization of phage cocktails with broad in vitro activity. Although bacteriophage therapy has long been investigated as a strategy for treating bacterial infections, few frameworks exist for developing phage combinations in a reproducible and scalable manner. The methods outlined here address this gap and aim to support the broader development of therapeutic assets available to combat antibiotic resistance.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Penke et al. (2026) studied this question.

synapsesocial.com/papers/6980ff49c1c9540dea81238ehttps://doi.org/10.1038/s41467-026-68684-x
Ask AI
Helpful
Bookmark
Share
View Full Paper